ASND — Ascendis Pharma A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612042 ·
Denmark
Last close
$225.60
Market Cap
$14.84B
52W High
$282.15
52W Low
$186.05
ADV30
730,710
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 339,285,000 | 311,627,000 | 220,465,000 | 206,970,000 | 2,286,020,000 | 812,260,000 | 849,529,000 |
| Mar 2026 | 246,601,000 | 229,086,000 | 24,812,000 | 629,339,000 | 2,003,279,000 | 572,820,000 | 1,515,306,000 |
| Dec 2025 | 247,500,000 | 223,902,000 | 6,442,000 | -33,562,000 | 1,302,570,000 | 616,041,000 | 1,465,391,000 |
| Sep 2025 | 213,634,000 | 191,280,000 | 10,997,000 | -60,989,000 | 1,154,750,000 | 539,092,000 | 1,328,825,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$60,489,000
Investing CF
$-14,535,000
Financing CF
$17,519,000
CapEx
$-8,485,000
Dividends Paid
—
Buybacks
$-51,857,000
EPS Diluted TTM
$7.38
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,666,427,000
Inventory
$314,342,000
Receivables
$196,607,000
ST Investments
$0
EBIT TTM
$-26,729,000
Pretax Income TTM
$-167,261,000
Interest Exp TTM
$140,532,000
Analysts
18
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,047,020,032
EBITDA
$263,454,000
Free Cash Flow
$12,771,750
Enterprise Value
$16,943,709,184
Total Cash
$812,259,968
Total Debt
$450,073,984
Shares Out
65,783,370
Trailing EPS
$13.02
Book Value
$25.38
ROE
118.8%
ROA
9.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 720,132,000 | -136,271,000 | -228,034,000 | 1,302,570,000 | 1,465,391,000 | -162,821,000 | 53,897,000 |
| Dec 2024 | 363,641,000 | -278,763,000 | -378,084,000 | 1,179,495,000 | 1,285,201,000 | -105,706,000 | -306,197,000 |
| Dec 2023 | 266,718,000 | -455,541,000 | -481,447,000 | 825,587,000 | 971,284,000 | -145,697,000 | -467,361,000 |
| Dec 2022 | 51,174,000 | -561,814,000 | -583,194,000 | 1,089,738,000 | 826,390,000 | 263,348,000 | -495,699,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.22
Max Pain — expiry 2026-10-16
max pain strike: $240.00 · spot: $225.29 · call oi: 2,529 · put oi: 1,186
Expected Move to 2026-10-16:
±$22.00
(9.77%) —
implied range
$203.29 –
$247.29
· ATM straddle on $230.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $15.45B | $237.95 | — |
| BBIO | BridgeBio Pharma, Inc. | $12.82B | $65.57 | — |
| CORT | CORCEPT THERAPEUTICS INC | $12.55B | $116.10 | — |
| SMMT | Summit Therapeutics Inc. | $12.45B | $15.61 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.93B | $516.56 | — |
News headlines (Yahoo Finance, 1h cache)
Ascendis Pharma (ASND) Authorizes $400M Share Buyback
2026-09-21 02:55 · Yahoo
Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
2026-09-19 10:09 · Yahoo
Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
2026-09-17 20:55 · Yahoo
Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
2026-09-16 14:46 · Yahoo
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
2026-09-15 13:12 · Yahoo
Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback
2026-09-15 08:37 · Yahoo
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
2026-09-14 22:00 · Yahoo
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
2026-09-12 17:02 · Yahoo
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
2026-09-10 13:52 · Yahoo
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
2026-09-09 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.